Clinical trials: Seasonal Human Influenza
Seasonal Influenza
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to <18 years of age).
- Trial name
- NCT07870330
- Testing
- mRNA-1010, Fluarix Trivalent
- Where
- 6 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Seasonal Influenza
A Study of Updated mRNA Seasonal Influenza Vaccines
The purpose of this study is to evaluate the immunogenicity and safety of updated strain-containing compositions of the mRNA-1010 vaccines within the current epidemiological environment.
- Trial name
- NCT07884175
- Testing
- mRNA-1010, Licensed High-Dose Seasonal Influenza Vaccine
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Seasonal Influenza
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase…
- Trial name
- NCT06602024
- Testing
- mRNA-1010, Fluarix®, Influsplit® Tetra
- Where
- 301 sites in United States, Belgium and 9 more
- Volunteers
- 40,805 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2, Seasonal Influenza
A Study of Modified mRNA Vaccines in Healthy Adults
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Trial name
- NCT05397223
- Testing
- mRNA-1273, mRNA-1010, mRNA-1345
- Where
- 8 sites in United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Seasonal Influenza
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
- Trial name
- IGNITE P303 (NCT05827978)
- Testing
- mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
- Where
- 103 sites in United States
- Volunteers
- 8,411 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Seasonal Influenza
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls…
- Trial name
- NCT05827068
- Testing
- mRNA-1011.1, mRNA-1011.2, mRNA-1012.1
- Where
- 22 sites in United States
- Volunteers
- 698 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Seasonal Influenza
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.
- Trial name
- NCT05566639
- Testing
- mRNA-1010, Fluarix Quadrivalent
- Where
- 233 sites in United States, Bulgaria and 9 more
- Volunteers
- 22,502 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Seasonal Influenza
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1020, mRNA-1030, and mRNA-1010 vaccines against vaccine-matched influenza A and B strains.
- Trial name
- NCT05333289
- Testing
- mRNA-1030, mRNA-1020, mRNA-1010
- Where
- 15 sites in United States
- Volunteers
- 572 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Seasonal Influenza
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.
- Trial name
- NCT04956575
- Testing
- mRNA-1010, Active Comparator
- Where
- 21 sites in United States
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19, Coronavirus Infections
Audio Data Collection for Identification and Classification of Coughing
An open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.
- Conditions
- COVID-19, Coronavirus Infections, Hay Fever, Asthma
- Trial name
- NCT04326309
- Where
- United States
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- HealthMode Inc.
Seasonal Influenza, Influenza
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a…
- Conditions
- Seasonal Influenza, Influenza, Influenza Due to Unspecified Influenza Virus, Human Influenza
- Trial name
- NCT01342796
- Testing
- MF59C.1-adjuvanted subunit influenza vaccine, Sub unit, Inactivated, Influenza vaccine
- Where
- 2 sites in Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Seasonal Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects
Influenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risks and elderly.
- Trial name
- NCT01161264
- Testing
- Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Seasonal Influenza
Yearly Strain Variation Study, 2010/2011
The purpose of the study is to verify the immunogenicity and tolerance of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2010/2011 season for yearly licensing application.
- Trial name
- NCT01157702
- Testing
- Inactivated influenza vaccine (split virus, Vero cell-derived)
- Where
- Austria
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Seasonal Influenza
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)
The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy children aged 6-35 months.
- Trial name
- NCT03859141
- Testing
- Quadrivalent influenza vaccine, Trivalent influenza vaccine (contains B/Victoria strain), Trivalent influenza vaccine (contains B/Yamagata strain)
- Where
- 2 sites in China
- Volunteers
- 2,340 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Seasonal Influenza
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)
The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy subjects aged over 3 years
- Trial name
- NCT03853993
- Testing
- Quadrivalent influenza vaccine, Trivalent influenza vaccine (contains B/Victoria strain), Trivalent influenza vaccine (contains B/Yamagata strain)
- Where
- 2 sites in China
- Volunteers
- 2,380 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Seasonal Influenza
Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010
This study is an annual trial for registration of inactivated split influenza vaccine with strain composition for season 2009/2010.
- Trial name
- NCT00945841
- Testing
- inactivated split influenza vaccine
- Where
- 3 sites in Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza, Seasonal Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the licensed seasonal flu vaccine, as measured by hemagglutination inhibition (HI) at 21 days post…
- Trial name
- NCT00956449
- Testing
- Seasonal Influenza Vaccine
- Where
- United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis
Seasonal Influenza, Vaccine
Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009
Annual trial for registration influenza vaccine with the strain composition for season 2008/2009
- Trial name
- NCT00735410
- Testing
- Seasonal Influenza Vaccine
- Where
- Germany
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Seasonal Influenza
Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009
Annual trial for registration influenza vaccine with the strain composition for season 2008/2009
- Trial name
- NCT00748813
- Testing
- Influenza Vaccine, Formulation 2008-2009
- Where
- 3 sites in Italy
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Seasonal Influenza, Vaccine
Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
Evaluation of the safety of Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in embryonated Hen Eggs in subjects 18 years of age and above with and without underlying medical conditions and…
- Trial name
- NCT00560066
- Testing
- Cell-derived influenza vaccine, Egg-derived influenza vaccine
- Where
- 15 sites in Germany
- Volunteers
- 1,398 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines